Promising Effects of Neurorestorative Diets on Motor, Cognitive, and Gastrointestinal Dysfunction after Symptom Development in a Mouse Model of Parkinson's Disease by Paula Perez-Pardo et al.
ORIGINAL RESEARCH
published: 20 March 2017
doi: 10.3389/fnagi.2017.00057
Frontiers in Aging Neuroscience | www.frontiersin.org 1 March 2017 | Volume 9 | Article 57
Edited by:
Changiz Geula,
Northwestern University, USA
Reviewed by:
Valentina Echeverria Moran,
Bay Pines VA Medical Center, USA
Anelyssa D’Abreu,
Brown University, USA
*Correspondence:
Aletta D. Kraneveld
A.D.Kraneveld@uu.nl
Received: 10 October 2016
Accepted: 27 February 2017
Published: 20 March 2017
Citation:
Perez-Pardo P, de Jong EM,
Broersen LM, van Wijk N, Attali A,
Garssen J and Kraneveld AD (2017)
Promising Effects of Neurorestorative
Diets on Motor, Cognitive, and
Gastrointestinal Dysfunction after
Symptom Development in a Mouse
Model of Parkinson’s Disease.
Front. Aging Neurosci. 9:57.
doi: 10.3389/fnagi.2017.00057
Promising Effects of
Neurorestorative Diets on Motor,
Cognitive, and Gastrointestinal
Dysfunction after Symptom
Development in a Mouse Model of
Parkinson’s Disease
Paula Perez-Pardo 1, Esther M. de Jong 1, Laus M. Broersen 1, 2, Nick van Wijk 2,
Amos Attali 2, Johan Garssen 1, 2 and Aletta D. Kraneveld 1*
1Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht,
Netherlands, 2Nutricia Research, Utrecht, Netherlands
Parkinson’s disease (PD) is characterized by the progressive degeneration of
dopaminergic nigrostriatal neurons, with reductions in the function and amount of
dopaminergic synapses. Therefore, synapse loss and membrane-related pathology
provide relevant targets for interventions in PD. We previously showed the beneficial
preventive effects of a dietary intervention containing uridine and DHA, two precursors
for membrane synthesis, in the intrastriatal rotenone model for PD. Here, we examined
the therapeutic potential of the same dietary intervention on motor, cognitive, and
gastrointestinal symptoms. In addition, we tested the effects of an extended nutritional
formula based on the same precursors plus other nutrients that increase membrane
phospholipid synthesis as well as prebiotic fibers. C57BL/6J mice received a unilateral
rotenone injection in the striatum. Dietary interventions started 28 days after surgery,
when motor-symptoms had developed. Readout parameters included behavioral tasks
measuring motor function and spatial memory as well as intestinal function and
histological examination of brain and gut to assess PD-like pathology. Our results show
that rotenone-induced motor and non-motor problems were partially alleviated by the
therapeutic dietary interventions providing uridine and DHA. The extended nutritional
intervention containing both precursors and other nutrients that increase phospholipid
synthesis as well as prebiotic fibers was more effective in normalizing rotenone-induced
motor and non-motor abnormalities. The latter diet also restored striatal DAT levels,
indicating its neurorestorative properties. This is the first study demonstrating beneficial
effects of specific dietary interventions, given after full development of symptoms, on a
broad spectrum of motor and non-motor symptoms in a mouse model for PD.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disease after Alzheimer’s disease (AD;
de Rijk et al., 2000; Nussbaum and Ellis, 2003). The clinical
picture is dominated by motor impairments due to a progressive
degeneration of dopaminergic nigrostriatal neurons, with
reductions in striatal dopamine levels, dopaminergic synapses,
and the density of dendritic spines on striatal medium spiny
neurons (Albin et al., 1989; Crossman, 1989). PD patients also
develop non-motor symptoms, including cognitive impairment
(Aarsland et al., 2003) and gastrointestinal (GI) dysfunctions
(Pfeiffer, 2011; Fasano et al., 2015). These non-motor symptoms
are major determinants of quality of life (Schrag et al., 2000;
Martinez-Martin et al., 2011; Müller et al., 2013) and remain
undertreated (Chaudhuri and Schapira, 2009).
The most commonly used drug in the treatment of PD is L-
Dopa that compensates for dopaminergic cell loss by enhancing
dopamine synthesis in the remaining terminals. This therapy
has several side effects (Schrag and Quinn, 2000), it does not
prevent dopaminergic neuron degeneration, and has no effects
on non-motor symptoms (Lee and Koh, 2015). Considering that
some of the non-responsive symptoms like GI dysfunctions may
contribute to L-Dopa response fluctuations (Poewe et al., 2010),
there is a clear need to develop additional therapies for PD
treatment.
Oral administration of two circulating phosphatide
precursors, uridine, and docosahexaenoic acid (DHA),
increases dopaminergic neurotransmission, synaptic membrane
formation, as well as the density of dendritic spines (Wang
et al., 2005; Sakamoto et al., 2007; Wurtman et al., 2009, 2010).
Indeed, preventive treatment with precursors uridine and DHA
reduced rotational behavior in the unilateral 6-OHDA rat model
for PD (Cansev et al., 2008). We have also shown beneficial
preventive effects of a dietary intervention containing uridine
and DHA in the intrastriatal rotenone mouse model for PD.
Intrastriatal injection of rotenone caused several motor and non-
motor symptoms associated with PD. The preventive dietary
intervention was not only effective for the motor symptoms but
also for the GI phenotype (Perez-Pardo et al., 2017).
In the present study we examine the therapeutic potential
of the same dietary intervention in the intrastriatal rotenone
mouse model of PD given after the development of full motor
symptoms, i.e., 4 weeks after rotenone injection, to elucidate
if the diet has neurorestorative properties. We also investigate
the therapeutic potential of an extended diet containing the
same dietary precursors (uridine and DHA) plus additional
nutrients that increase membrane phospholipid synthesis and
prebiotic fibers. The additional nutrients displayed synergistic
effects with the precursors in enhancing synapse formation and
function, in counteracting loss of functional connectivity in
neurodegeneration, and in improving behavior and cognitive
functions (van Wijk et al., 2014). In mouse models of Alzheimer-
like pathology, the extended diet showed higher efficacy than
interventions with single nutrients or incomplete formulations
(Broersen et al., 2013; Zerbi et al., 2014). Prebiotic fibers have
been shown to have beneficial effects on immune function (van
Hoffen et al., 2009; de Kivit et al., 2011; Jeurink et al., 2013), bowel
motility and constipation (Rasmussen et al., 2014; Scholtens et al.,
2014; Meksawan et al., 2016) relevant for inflammation and
GI-related symptoms in PD.
MATERIALS AND METHODS
Mice
Seven week-old C57BL/6J mice (Charles River, The Netherlands)
were housed at room temperature under 12 h light/dark cycle.
Food and water was provided ad libitum. All animal procedures
were approved by the Ethical Committee of Animal Research of
Utrecht University, The Netherlands.
Surgery
Mice underwent stereotaxic surgery under isoflurane anesthesia:
a hole was drilled in the skull, a cannula inserted in the right
striatum and 5.4µg of freshly prepared rotenone (dissolved in
2µl DMSO) was infused. The following stereotaxic coordinates
were used: AP+0.4, ML−2.0 (from bregma) and DV−3.3 below
dura. Sham-treated animals were injected with vehicle. Tenweeks
after surgery the mice were euthanized by decapitation.
Diets
Mice were fed either the Control diet, Diet1, or Diet2, starting
28 days after surgery when motor symptoms leveled out and
continuing for the duration of the experiment. Animals were
divided into six groups (n = 10), as specified in Table 1. Iso-
caloric diets were produced by Research Diet Services (Wijk bij
Duurstede, The Netherlands) and were based on the Control diet,
i.e., the standard animal food for laboratory rodents AIN-93 M
(Reeves et al., 1993) with 5% fat. For Diet1, UMP as a source of
uridine (0.51/100 g diet) was added and part of the lipid blend of
control diet was replaced by fish oil, providing DHA (0.74/100 g
diet) and EPA (0.29/100 g diet).
Diet2 provided the phospholipid precursors from Diet1, but
also choline, phospholipids, selenium, folic acid, and vitamins B6,
B12, C, D, and E. The fish oil in Diet2 provided DHA (0.75/100 g
diet) and EPA (0.50/100 g diet). In addition, the cellulose fibers
from Control diet and Diet1 were replaced by prebiotic fibers
(1.5/100 g diet GOS, 0.17/100 g diet lcFOS, 1.67/100 g diet scFOS,
and 1.67/100 g diet nutriose) for Diet2. Further, specifications of
the diets are listed in Table 2.
Motor Symptoms Assessment
The motor function of each mouse was assessed by the Rotarod
test as described before (Inden et al., 2007). Briefly, mice were
placed on an accelerating rod with speeds starting with 2 rpm
and gradually increasing to 20 rpm. Time to first fall was recorded
for a maximum of 300 s. The test was performed at baseline and
after every 5 days until day 70, in order to look at symptom
development in time and functional recovery during dietary
intervention.
Muscle strength of the four limbs was measured on day 70
after surgery using the inverted screen test as described before
(Deacon, 2013). Briefly, the mouse was placed in the center of a
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TABLE 1 | Specification of the 6 experimental groups.
Experimental groups Nutritional intervention
Control diet Diet1 Diet2
Surgery Sham 1. Sham surgery + Control diet
throughout the experiment
2. Sham surgery + Diet1 starting 4
weeks after surgery
3. Sham surgery + Diet2 starting 4
weeks after surgery
Rotenone 4. Rotenone injection + Control diet
throughout the experiment
5. Rotenone injection + Diet1 starting
4 weeks after surgery
6. Rotenone injection + Diet2
starting 4 weeks after surgery
TABLE 2 | Compositions of the experimental diets.
Experimental diets Control
(g/100 g)
Diet 1
(g/100 g)
Diet 2
(g/100 g)
Proteins 14.0 14.0 14.0
Carbohydrates 71.0 70.6 68.7
Fats 5.0 5.0 5.0
Soy oil 1.9
Coconut oil 0.9 0.1 0.2
Corn oil 2.2 1.7 1.2
Fish oil 3.2 3.6
Providing DHA 0.74 0.75
Providing EPA 0.29 0.50
Mineral mix (AIN-93M-MX) 3.5 3.5 3.5
Vitamin mix (AIN-93-VX) 1.0 1.0 1.0
Fibers 5.0 5.0 5.0
Cellulose 5.0 5.0
GOS 1.50
IcFOS 0.17
ScFOS 1.67
Nutriose 1.67
Additions
L-cystine 0.18 0.18 0.18
Choline bitartrate 0.25 0.25 0.25
Tert-butylhydroquinone 0.0008 0.0008 0.0008
Uridine 0.51 0.51
Choline chloride 0.40
Soy lecithin 0.75
Sodium selenite 0.00023
Pyridoxine 0.0041
Folic acid 0.00067
Cyanocobalamin 0.058
Ascorbic acid 0.16
Di-a-tocopheryl acetate (500 IU/g) 0.47
Cholecalciferol (400,000 IU/g) 0.00031
wire mesh screen, which was subsequently rotated to an inverted
position. Latency to fall was measured in seconds.
Muscular forelimb strength was also measured on day 70 with
a grip strength tester as described before (Leiter et al., 2011).
Spatial Recognition Test
Animals’ ability to react to a spatial novelty after a 3-min delay
was measured every 14 days after surgery and for the duration
of the experiment, to assess model- and diet-induced changes
over time. As described before (De Leonibus et al., 2007), mice
were individually submitted to seven consecutive, 6-min sessions.
During session 1, mice were placed into the empty open field.
During sessions 2–4, five objects were present, and mice were
placed into the apparatus to habituate to the objects configuration
(habituation phase). During the 3-min intersession interval, the
animals were returned to a waiting cage. During the spatial test
session (session 5), the objects configuration was changed by
moving two objects (displaced objects, DO) and leaving the other
three objects in the same position (non-displaced objects, NDO).
In all sessions, the total activity of the animal wasmeasured. From
sessions 2–5, object exploration was evaluated on the basis of
the mean time spent by the animal in contact with the different
objects. The animals’ ability to selectively react to the spatial
change was analyzed by calculating the spatial re-exploration
index (DO[S5] − DO[S4] = DO and NDO[S5] − NDO[S4] =
NDO). The time the animals interact with the DOminus the time
they interact with the NDO is used for analysis (DO-NDO). Data
are expressed as percentage with respect to baseline (day 14).
Intestinal Transit and Colon Length
Intestinal transit was assessed in all animals. Thirty minutes
before sacrificing the mice, a 2.5% Evans blue solution in
1.5% methylcellulose (0.3mL per animal) was intragastrically
administered. After euthanasia, intestinal transit was measured
as the distance from the pylorus to the most distal point of
migration of the Evans blue dye. In addition, the length of the
colon was measured.
Tissue Preparation and
Immunohistochemistry
Coronal slices of 40µm were sectioned using a cryostat
(CM3050, Leica Microsystems). Sections were incubated with
0.3% H2O2 for 30 min. Following blocking serum, sections
were incubated overnight with rabbit anti-tyrosine hydroxylase
(TH; Santa-Cruz Biotechnology) 1:1000 or with rat anti-
dopamine transporter (DAT) 1:1000. Next day, sections were
incubated with the appropriate biotinylated secondary antibody
(Jackson ImmunoResearch) 1:200 for 2 h. The avidin-biotin
method was used to amplify the signal (ABC Kit, Vector)
and 3,3′-diaminobenzidine tetrachloride (DAB) was used as the
chromogen.
The colons of the animals were embedded in paraffin. 15µm
sections were incubated with 0.3% H2O2 for 30 min, rehydrated
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and incubated with citrate buffer. Following serum block,
sections were incubated overnight with the primary antibodies
[rabbit anti-alpha-synuclein (1:1,000, millipore), rabbit anti-
GFAP (1:1,000, Dako) or rabbit anti-CD3 (1:1,000, abcam)].
For alpha-synuclein and GFAP, slides were incubated with
a fluorescent secondary antibody: Alexa R©488 donkey anti-
rabbit and mounted using Vectashield R© mounting medium for
fluorescence with DAPI (Vectro Laboratories). For CD3 staining,
a biotinylated secondary antibody (1:200, Dako) was used. The
avidin-biotinmethodwas used to amplify the signal andDABwas
used as chromogen. Sections were counterstained with Mayer’s
haematoxylin (Merck Millipore).
Image Analysis
For immunostained sections, digital images were captured
with an Olympus BX50 microscope equipped with a Leica
DFC 320 digital camera. To count TH-immunopositive cells,
every fourth section of each mouse brain was stained. TH-
immunopositive neurons were quantified stereologically on
regular spaced sections. To measure DAT and alpha-synuclein
expression the optical density in the area of interest wasmeasured
and corrected for non-specific background. Stereology was
performed to quantify the number of CD3 positive cells in the
colon on regular spaced sections. Analysis were performed by
researchers that were blind to the treatment condition of the
animal. Immunofluorescence images were made using a Keyence
BZ-9000 microscope. The Corrected Total Fluorescence (CTF)
was calculated with the formula: integrated density − (area ×
mean fluorescence of background reading).
Statistical Analysis
Experimental results are expressed as mean ± SEM. Differences
between groups were statistically analyzed with a two-way
ANOVA [analyzing significant effects of the treatments (rotenone
vs. vehicle), diets (control diet, Diet1, and Diet2) and interactions
(between diets and treatment)] followed by a Tukey’s multiple
comparison test. For the rotarod test and spatial memory test,
data were analyzed with a general linear model repeated measure
ANOVA with the within subject factor time and the between
subject factors treatment and diet. Results were considered
statistically significant when p < 0.05. Analyses were performed
using SPSS 22.0.
RESULTS
Dietary Interventions Have a Restorative
Effect on Rotenone-Induced Motor
Symptoms
To investigate whether dietary intake affected rotenone-induced
motor dysfunction, the rotarod test was performed. The time
spent on the rod was used for analysis of motor function. There
was an overall effect of treatment (rotenone vs. vehicle) [F(1, 44)
= 492.62, p < 0.0001] and of diet [F(2, 44) = 3.60, p < 0.05]
on rotarod performance. Repeated measures showed an effect
of time [F(13, 572) = 50.58, p < 0.0001]. Rotenone-injected
mice developed motor dysfunction over time compared to sham
(interaction effect treatment x time F(13, 572) = 59.25 p< 0.0001].
Furthermore, there was an interaction effect between diet and
time [F(26, 572) = 2.16, p < 0.01], between diet and treatment
[F(2, 44) = 3.55, p < 0.05] and between diet, treatment and time
[F(26, 572) = 2.15, p < 0.01]. Rotenone-injected mice showed a
decrease in rotarod performance starting on day 25 after surgery
compared to the sham-operated mice [F(1, 54) = 226.41, p <
0.0001]. On day 55 after surgery there was a significant effect of
the diets [F(2, 53) = 3.30, p < 0.05] on rotarod performance that
remained for the duration of the experiment [F(2, 54) = 8.87, p <
0.0001 day 70]. Post-hoc analysis showed that rotenone-treated
animals on Diet1 performed better on the rotarod compared
to rotenone-treated animals on control diet starting from day
65 (p < 0.05). Rotenone-treated animals on Diet2 remained
longer on the rod compared to rotenone treated animals on
control diet starting from day 55 (p < 0.01). Moreover, Diet2
was significantly more effective in normalizing rotenone-induced
motor-dysfunction compared to Diet1 (Figure 1A).
Muscle strength was measured with the inverted screen test 70
days after surgery, where the latency to fall was used for analysis.
Significant differences were observed in the latency to fall of
rotenone-injected mice compared to sham [F(1, 53) = 417.5,
p < 0.0001]. There was an overall effect of diet [F(2, 53) = 17.41,
p < 0.0001] and a diet by treatment interaction [F(2, 53) = 13.10,
p < 0.0001]. Post-hoc analysis revealed an increase in the latency
to fall in the test in rotenone-treated mice on Diet1 (p < 0.01)
and Diet2 (p < 0.0001) compared to rotenone-treated mice on
Control diet. The extended nutritional intervention (Diet2) was
more effective than Diet1 in reducing rotenone-induced muscle
strength loss (p < 0.01; Figure 1B).
Similar results were found in the forelimb grip strength test,
rotenone-treated animals showed a decrease in their forelimb
grip strength compared to sham [F(1, 53) = 130.1, p < 0.0001] 70
days after surgery. The diet had an overall effect on grip strength
[F(2, 53) = 14.7, p < 0.0001] and there was a diet by treatment
interaction [F(2, 53) = 9.3, p < 0.001]. More specifically,
rotenone-injected mice fed the Diet1 and the Diet2 had more
strength in the forelimbs compared to rotenone-injected mice on
Control diet (p < 0.01 and p < 0.0001, respectively). Diet2 was
again more effective than Diet1 in reducing rotenone-induced
forelimb grip strength loss (p < 0.05; Figure 1C).
Dietary Interventions Have No Effects on
Rotenone-Induced Dopaminergic Cell Loss
but Diet2 Has Restorative Effects on
Dopamine Transporter Expression
To investigate the motor impairments associated
neurodegeneration, we performed unbiased stereology to
estimate the number of TH positive dopaminergic cells in the
SN. Seventy days after surgery rotenone-treated mice showed
a decrease in the number of TH positive cells compared to
vehicle-injected mice [F(1, 30) = 76.17, p< 0.001]. No differences
were found in the total number of TH positive cells in the SN
between the two brain hemispheres. There was no overall effect
of diet [F(2, 30) = 0.57, p = 0.57] and no significant interaction
between treatment and diet [F(2, 30) = 0.90, p= 0.42; Figure 2A).
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FIGURE 1 | Effects of the dietary interventions that were started after development of full motor dysfunction on motor symptoms; (A) rotarod
performance, (B) inverted screen test, and (C) forelimb grip strength test. Unilateral rotenone injection induced motor dysfunction and grip strength loss. Dietary
interventions had beneficial effects on motor function and grip strength. The extended nutritional intervention (Diet2) was more effective than Diet1 for all the tests.
Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001. (n = 10 per group).
Dopamine transporter (DAT) expression was measured in
the striatum by measuring the optical density after DAT
immunostaining. Rotenone caused a decrease in DAT expression
in the striatum [F(1, 36) = 26.49, p< 0.0001] 70 days after surgery.
Unilateral-injection of rotenone caused a bilateral reduction of
the DAT expression in the striatum; no differences were found
in DAT immunoreactivity between the two brain hemispheres.
There was an overall effect of the diets on DAT expression
[F(2, 36) = 3.44, p < 0.05; Figure 2B]. Diet2 increased DAT
expression as compared to Control diet in rotenone-treated mice,
in the absence of a significant treatment by diet interaction.
Diet 2 Has Restorative Effects on
Rotenone-Induced Spatial Recognition
Impairment
Sham-operated animals selectively re-explored the displace
object (DO) as compared to the non-displaced object (NDO)
during the whole experiment, demonstrating that they were able
to selectively react to the spatial change. Rotenone treatment
negatively affected the rodents’ ability to react to a spatial novelty
[F(1, 54) = 4.701, p < 0.05]. Repeated measures showed an effect
of time [F(4, 216) = 11.06, p < 0.0001] and an effect of rotenone
over time [F(4, 216) = 5.82, p < 0.0001]. Spatial recognition
was affected by rotenone from day 42 after surgery onwards
[F(1, 54) = 7.10, p < 0.05] and by the diet on day 56 after
surgery [day 28 after dietary interventions started; F(2, 54) =
3.52, p < 0.05]. Post-hoc comparisons showed no differences
in spatial discrimination abilities between rotenone-treated mice
on Control diet and on Diet1. However, rotenone-injected mice
on Diet2 had a better spatial recognition than rotenone-injected
animals on Control diet (p < 0.05) on day 70 (Figure 3). No
significant differences were found in the total activity in the open
field between experimental groups.
Diet 2 Has a Restorative Effect on
Rotenone-Induced Gastrointestinal
Dysfunction
Rotenone injection in the striatum negatively affected intestinal
transit, i.e., decreased the distance traveled by the Evans Blue dye
in the GI-tract, as compared to vehicle-injected mice [F(1, 51) =
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FIGURE 2 | Effects of dietary interventions that were started after development of full motor dysfunction on (A) the number of dopaminergic cells indicated
by the number of tyrosine hydroxylase (TH) immunoreactive cells in the substantia nigra and (B) dopamine transporter (DAT) expression in the striatum. Photographs
show typical examples of TH and DAT immunostaining of substantia nigra and striatum, respectively, from all treatment groups. Rotenone injection decreased the
number of dopaminergic cells in the substantia nigra and the level of DAT expression in the striatum. No differences were found in the number of TH positive cells and
DAT expression between hemispheres after unilateral injection of rotenone. Dietary interventions had no effect on the number of TH positive cells but Diet2 increased
DAT expression. Data are shown as mean ± SEM. *p < 0.05, ***p < 0.001. (Scale bar: 200 µm applies to all panels). (n = 6 for TH immunostaining and n = 4 for DAT
immunostaining).
18.81, p< 0.0001]. There was an overall effect of diet on intestinal
transit [F(2, 51) = 4.19, p< 0.05] and an interaction effect between
treatment and diet [F(2, 51) = 3.33, p< 0.05]. The beneficial effect
of Diet2 on intestinal transit after rotenone exposure was more
pronounced (p < 0.001; Figure 4A).
Dietary Interventions Have a Restorative
Effect on Rotenone-Induced
Alpha-Synuclein Accumulation in the Colon
Rotenone administration in the striatum increased alpha-
synuclein accumulation in the enteric plexus of the colon
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FIGURE 3 | Effects of dietary interventions that were started after development of full motor dysfunction on spatial object recognition test.
Sham-operated animals selectively re-explored the displace object (DO) as compared to the non-displaced object (NDO) throughout the experiment. Rotenone
decreased animals’ ability to react to a spatial novelty from day 42 after surgery onwards. On day 70 after surgery, rotenone-injected animals on Diet2 showed better
spatial discrimination abilities compared to rotenone-injected animals on control diet. Data are shown as mean ± SEM. **p < 0.01, ****p < 0.0001 compared to Sham
+ Control food. ##p < 0.01 compared to Rotenone + Control food (n = 10 per group).
compared to vehicle exposed mice [F(1, 51) = 72.14, p < 0.0001].
There was an effect of diet on alpha-synuclein accumulation in
the colon [F(2, 51) = 3.56, p < 0.05]. Post-hoc analysis revealed
a reduction in alpha-synuclein levels for rotenone-injected mice
on Diet1 and Diet2 compared to rotenone-injected mice on
Control diet (both p < 0.05). No differences were found in
alpha-synuclein levels for rotenone-animals on Diet1 compared
to rotenone-treated animals on Diet2 (Figure 4B).
Dietary Interventions Have a Restorative
Effect on Rotenone-Induced Inflammation
in the Gut
To measure reactive enteric glial cells in the enteric nervous
system (ENS) of the colon, GFAP (glial fibrillary acidic protein)
expression was quantified after immunostaining. Rotenone
exposure in the brain increased GFAP expression in the colon
[F(1, 54) = 23.94, p < 0.0001]. There was also an effect of diet
[F(2, 54) = 6.36, p < 0.01] and an interaction effect between
diet and treatment [F(2, 54) = 7.83, p < 0.01]. Post-hoc analysis
showed that GFAP expression was normalized in rotenone-
injected mice on Diet1 or Diet2 compared to rotenone-treated
animals on Control diet (both p < 0.001; Figure 4C).
The length of the colon of all the animals was measured as a
gross indicator of inflammation. There was an overall effect of
the treatment [rotenone vs. vehicle; F(1, 54) = 72.25, p < 0.0001]
as well as an effect of diet [F(2, 54) = 10.42, p < 0.001] and an
interaction effect between treatment and diet [F(2, 54) = 7.32, p<
0.01]. More specifically, rotenone-treated animals on Diet1 and
Diet2 revealed a smaller decrease in colon length compared to the
ones on Control diet (p< 0.0001 and p< 0.001, respectively). No
differences in colon length were found between rotenone-treated
mice on Diet1 and rotenone-treated mice on Diet2 (Figure 5A).
The number of T-cells in the colon was increased after
rotenone injection in the brain [F(1, 36) = 51.41, p < 0.0001].
There was an effect of diet [F(2, 36) = 17.48, p < 0.0001] and an
interaction effect between treatment and diet [F(2, 36) = 12.80,
p < 0.0001]. Post-hoc analysis revealed that rotenone-injected
mice on Diet1 and Diet2 had less infiltration of T-cells in the
colon compared to rotenone-injected mice on Control diet (p <
0.001 and p< 0.0001, respectively). Diet2 was more effective than
Diet1 in reducing rotenone-induced T-cell infiltration (p < 0.05;
Figure 5B).
DISCUSSION
In the present study we replicated previous finding (Perez-
Pardo et al., 2017) by showing that unilateral rotenone injection
in the striatum caused a disturbed motor function, bilateral
dopaminergic cell loss in the SN, delayed intestinal transit, alpha-
synuclein accumulation in the ENS, and colonic inflammation. In
addition, we demonstrated that intrastriatal rotenone injection
caused grip strength loss, spatial recognition deficits, and an
increase in the amount of reactive enteric glial cells in the
colon. These new findings broaden the range of motor and
non-motor symptoms observed and increase the relevance of
the model for PD in patients where cognitive symptoms (Boller
et al., 1984; Giraudo et al., 1997) and increased inflammation
markers in colonic biopsies are reported (Clairembault et al.,
2014). Furthermore, in our mouse model the spatial recognition
deficits developed later than the motor dysfunction, similar to
PD patients where cognitive symptoms tend to occur later in
the course of the disease. Therefore, the intrastriatal rotenone
model in mice is a consistent model of PD that recapitulates
key features of the pathology and symptomatology observed in
humans. Whether other non-motor symptoms, in addition to
cognitive and gastrointestinal dysfunction, are also induced by
the model remains to be determined.
In the present study we also extended our recent observations
regarding the effects of specific dietary interventions on a broad
range of motor and non-motor symptoms in this mouse model of
PD. It was previously shown that uridine and DHA were able to
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FIGURE 4 | Effects of dietary interventions that were started after development of full motor dysfunction on: (A) intestinal transit indicated by the total
distance traveled by the Evans blue dye in the GI tract 30 min after its injection by oral gavage, (B) alpha-synuclein expression in the colon and (C) on enteric glial cells
expression in the colon as indicated by the glial fibrillary acidic protein (GFAP). Rotenone injection reduced intestinal transit time and increased alpha-synuclein (shown
in green) and GFAP (shown in red) expression in the myenteric and submucosal plexus of the colon. Dietary interventions improved rotenone-induced delayed intestinal
transit and reduced rotenone-induced alpha-synuclein and GFAP overexpression in the colon. The beneficial effect of Diet2 on intestinal transit after rotenone exposure
was more pronounced that the effect of Diet1. The Corrected Total Fluorescence (CTF) was calculated with the formula: integrated density-(area × mean fluorescence
of background reading). Data are shown as mean ± SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. (Scale bar: 50µm applies to all panels) (n = 9 or 10 per group).
reduce circling behavior in the 6-OHDA animal model (Cansev
et al., 2008) and we showed that uridine and DHA prevented
the induction of motor deficits as well as the development
of GI dysfunctions in rotenone models of PD (Perez-Pardo
et al., 2017). Here, we show that the same diet (Diet1) given
after the occurrence of motor problems, was able to reduce
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motor dysfunction, grip strength loss, cognitive deficits, delayed
intestinal transit, colonic inflammation, and alpha-synuclein
accumulation in the ENS. This is the first study demonstrating
a clear therapeutic effect of specific dietary interventions in a
mouse model for PD.
Dietary interventions were started after the motor symptoms
had clearly developed. As a consequence, we see no effects of the
diets on the number of dopaminergic cells in the SN, indicating
that the diets did not reduce the loss of dopaminergic cells, i.e.,
they did not interfere with rotenone toxicity. The diets helped
to improve the functioning of the remaining dopaminergic
neurons, demonstrating that they have neurorestorative
properties and therefore may have disease-modifying
potential.
There are several relevant mechanisms that may have
contributed to the restoration of functions observed in the
present study. A series of animal studies have shown that
combined intake of phospholipid precursors including uridine
and omega-3 fatty acids such as DHA, can increase brain
phospholipid levels, synaptic protein levels, neurite outgrowth,
dendritic spine formation, and dopaminergic neurotransmission
(Wang et al., 2005; Sakamoto et al., 2007; Wurtman et al., 2009,
2010). Similarly to previous observations in the 6-OHDA rat
model of PD, where uridine plus DHA restored nigrostriatal
markers and ameliorated biochemical defects (Cansev et al.,
2008), it is likely that a diet-induced enhancement of functional
connectivity may underlie the presently observed recovery from
behavioral deficits.
In addition to replicating the beneficial effects of Diet1
in the striatal rotenone model, we show that the extended
nutritional intervention (Diet2) containing both precursors and
other nutrients that increase phospholipid synthesis as well as
prebiotic fibers was more effective in normalizing rotenone-
induced motor and non-motor abnormalities. Although the
present study was not designed to test the contribution of all
individual nutrients, there are several factors that may have
contributed to this enhanced effectiveness.
First, Diet2 contained specific prebiotic fibers such as
fructo-oligosaccharides and galacto-oligosaccharides that have
previously been shown to have beneficial effects on immune
function (van Hoffen et al., 2009; de Kivit et al., 2011), bowel
motility, and constipation (Scholtens et al., 2014; Meksawan
et al., 2016), by altering the microbiota composition and
their metabolic activity. Changes in microbiota composition
might also alter the enteric immune and nervous system
and subsequently the central nervous system (Maslowski and
Mackay, 2011; Clemente et al., 2012; Cryan and Dinan, 2015).
In addition, the prebiotic fibers have microbiota-independent
immunomodulatory properties (de Kivit et al., 2013). Thus,
adding prebiotic fibers in Diet2 may have contributed to its better
effects on intestinal transit and colonic inflammation compared
to Diet1, and possibly also to the beneficial effects on motor and
cognitive functioning.
Second, Diet2 contained a broader combination of nutrients
that has been shown to act synergistically to increase the
synthesis of synaptic membranes (van Wijk et al., 2014). On the
one hand it contained a full set of precursors for membrane
FIGURE 5 | Effects of dietary interventions that were started after
development of full motor dysfunction on (A) colon length and (B) the
number of T-cells in the colon. Photographs show typical examples of T-cell
immunostaining in the colon from all treatment groups. Rotenone reduced the
length of the colon and increased the number of T-cells (shown in brown). Both
dietary interventions increased rotenone-induced reduction of the colon and
reduced T-cell infiltration. Diet2 was more effective in normalizing rotenone
induced T-cell infiltration than Diet1. Data are shown as mean ± SEM.
*p < 0.05, ***p < 0.001, ****p < 0.0001. (Scale bar: 50 µm applies to all
panels). (n = 10 per group for colon length and n = 7 for T-cell infiltration 10).
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synthesis (i.e., DHA, EPA, uridine, choline, and phospholipids)
that act by enhancing the substrate-saturation of the enzymes that
catalyze the rate-limiting steps of phospholipid synthesis. On the
other hand it also contained B-vitamins, vitamin C, vitamin E,
selenium, and phospholipids that act as cofactors by increasing
the availability of membrane precursors or by directly affecting
the neuronal membrane or membrane synthesis (van Wijk et al.,
2014, 2016). Next to synergies between individual precursors
(Wurtman et al., 2009, 2010), the added value of the cofactors
has for instance been reported on the activation of G-protein-
coupled receptors (Savelkoul et al., 2012). In several in vivo
experiments, the diet has repeatedly been shown to be more
effective than supplementation of single nutrients or incomplete
nutritional combinations (Broersen et al., 2013; Zerbi et al., 2014;
Janickova et al., 2015). Also in the present study Diet2 was more
effective than the combination of uridine plus DHA (Diet1)
on all functional and behavioral parameters. In addition, only
intervention with this extended diet resulted in a restoration
of the expression of DAT in the striatum, which might be one
of the mechanisms by which the diet enhances dopaminergic
transmission in the remaining nigrostriatal neurons resulting
in a better functional output. Together these data suggest that
especially the combined intake of these nutrients, rather than
the use of single component supplements, could be beneficial to
maintain brain structure and function.
The present results regarding the effectiveness of the
extended dietary intervention (Diet2) in restoring functional
connectivity in the rotenone model of PD are in line with
previous observations in other models of either ongoing
neurodegeneration (Jansen et al., 2013; Wiesmann et al., 2016) or
acute neurotrauma (Pallier et al., 2015; Wiesmann et al., 2017).
In these experiments Diet2 improved both neuronal connectivity
and behavioral output, suggesting a broad applicability of
this nutritional technology. This, together with positive results
regarding improved brain connectivity and functioning obtained
in patients with AD (Scheltens et al., 2012; de Waal et al.,
2014) and preliminary findings in patients with frontotemporal
dementia (Pardini et al., 2015), as well as a favorable safety profile
of the intervention (Cummings et al., 2017) warrant further
clinical testing in other patient populations (Cummings, 2012),
including PD.
In summary, our study demonstrated clear therapeutic effects
of specific dietary interventions in a mouse model of PD given
after disease induction. The extended nutritional intervention
(Diet2) was more effective than supplementation of only uridine
and DHA (Diet1) in normalizing rotenone-induced motor and
non-motor symptoms and PD-like pathologies in brain and
gut. Our results suggest that this nutritional intervention might
confer clinical benefits to patients suffering from PD.
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